|
Name |
Tryprostatin A
|
Molecular Formula | C22H27N3O3 | |
IUPAC Name* |
(3S,8aS)-3-[[6-methoxy-2-(3-methylbut-2-enyl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC(=CCC1=C(C2=C(N1)C=C(C=C2)OC)C[C@H]3C(=O)N4CCC[C@H]4C(=O)N3)C
|
|
InChI |
InChI=1S/C22H27N3O3/c1-13(2)6-9-17-16(15-8-7-14(28-3)11-18(15)23-17)12-19-22(27)25-10-4-5-20(25)21(26)24-19/h6-8,11,19-20,23H,4-5,9-10,12H2,1-3H3,(H,24,26)/t19-,20-/m0/s1
|
|
InChIKey |
XNRPVPHNDQHWLJ-PMACEKPBSA-N
|
|
Synonyms |
Tryprostatin A; CHEBI:72761; TPS-A; 171864-80-5; (3S,8aS)-3-[[6-methoxy-2-(3-methylbut-2-enyl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; (3S,8aS)-3-{[6-methoxy-2-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; TryprostatinA; CHEMBL289159; MEGxm0_000107; SCHEMBL21263139; DTXSID701017629; BDBM50198769; C20607; Q27140127
|
|
CAS | 171864-80-5 | |
PubChem CID | 9929833 | |
ChEMBL ID | CHEMBL289159 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 381.5 | ALogp: | 3.4 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 74.4 | Aromatic Rings: | 4 |
Heavy Atoms: | 28 | QED Weighted: | 0.779 |
Caco-2 Permeability: | -4.89 | MDCK Permeability: | 0.00000798 |
Pgp-inhibitor: | 0.047 | Pgp-substrate: | 0.837 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.538 |
30% Bioavailability (F30%): | 0.653 |
Blood-Brain-Barrier Penetration (BBB): | 0.725 | Plasma Protein Binding (PPB): | 87.79% |
Volume Distribution (VD): | 0.961 | Fu: | 6.78% |
CYP1A2-inhibitor: | 0.276 | CYP1A2-substrate: | 0.663 |
CYP2C19-inhibitor: | 0.898 | CYP2C19-substrate: | 0.449 |
CYP2C9-inhibitor: | 0.597 | CYP2C9-substrate: | 0.857 |
CYP2D6-inhibitor: | 0.212 | CYP2D6-substrate: | 0.863 |
CYP3A4-inhibitor: | 0.902 | CYP3A4-substrate: | 0.478 |
Clearance (CL): | 8.195 | Half-life (T1/2): | 0.477 |
hERG Blockers: | 0.113 | Human Hepatotoxicity (H-HT): | 0.969 |
Drug-inuced Liver Injury (DILI): | 0.2 | AMES Toxicity: | 0.017 |
Rat Oral Acute Toxicity: | 0.92 | Maximum Recommended Daily Dose: | 0.85 |
Skin Sensitization: | 0.514 | Carcinogencity: | 0.085 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.435 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001926 | 0.759 | D0AN7B | 0.270 | ||||
ENC002519 | 0.758 | D06HBQ | 0.255 | ||||
ENC001060 | 0.534 | D0J4JM | 0.253 | ||||
ENC002274 | 0.534 | D09ZIO | 0.253 | ||||
ENC000981 | 0.520 | D02DPU | 0.253 | ||||
ENC004933 | 0.520 | D0G8NJ | 0.251 | ||||
ENC003218 | 0.515 | D0C6DT | 0.248 | ||||
ENC001958 | 0.500 | D01XNB | 0.248 | ||||
ENC003264 | 0.500 | D03QGM | 0.246 | ||||
ENC003322 | 0.495 | D09OBB | 0.245 |